CD8A and neoplasm: In these radioresistant tumors, the combination of radiotherapy with anti-CD25 and anti-CD137 therapies may stimulate the activation of CD103+ DCs within the tumor-draining lymph nodes, leading to a CD8+ T-cell-dependent immune response.